Cargando…
Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles
Biofilms are aggregate of microorganisms in which cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS) and adhere to each other and/or to a surface. The development of biofilm affords pathogens significantly increased tolerances to antibiotics and an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465149/ https://www.ncbi.nlm.nih.gov/pubmed/32796745 http://dx.doi.org/10.3390/microorganisms8081222 |
_version_ | 1783577524093059072 |
---|---|
author | Jiang, Yu Geng, Mengxin Bai, Liping |
author_facet | Jiang, Yu Geng, Mengxin Bai, Liping |
author_sort | Jiang, Yu |
collection | PubMed |
description | Biofilms are aggregate of microorganisms in which cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS) and adhere to each other and/or to a surface. The development of biofilm affords pathogens significantly increased tolerances to antibiotics and antimicrobials. Up to 80% of human bacterial infections are biofilm-associated. Dispersal of biofilms can turn microbial cells into their more vulnerable planktonic phenotype and improve the therapeutic effect of antimicrobials. In this review, we focus on multiple therapeutic strategies that are currently being developed to target important structural and functional characteristics and drug resistance mechanisms of biofilms. We thoroughly discuss the current biofilm targeting strategies from four major aspects—targeting EPS, dispersal molecules, targeting quorum sensing, and targeting dormant cells. We explain each aspect with examples and discuss the main hurdles in the development of biofilm dispersal agents in order to provide a rationale for multi-targeted therapy strategies that target the complicated biofilms. Biofilm dispersal is a promising research direction to treat biofilm-associated infections in the future, and more in vivo experiments should be performed to ensure the efficacy of these therapeutic agents before being used in clinic. |
format | Online Article Text |
id | pubmed-7465149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74651492020-09-04 Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles Jiang, Yu Geng, Mengxin Bai, Liping Microorganisms Review Biofilms are aggregate of microorganisms in which cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS) and adhere to each other and/or to a surface. The development of biofilm affords pathogens significantly increased tolerances to antibiotics and antimicrobials. Up to 80% of human bacterial infections are biofilm-associated. Dispersal of biofilms can turn microbial cells into their more vulnerable planktonic phenotype and improve the therapeutic effect of antimicrobials. In this review, we focus on multiple therapeutic strategies that are currently being developed to target important structural and functional characteristics and drug resistance mechanisms of biofilms. We thoroughly discuss the current biofilm targeting strategies from four major aspects—targeting EPS, dispersal molecules, targeting quorum sensing, and targeting dormant cells. We explain each aspect with examples and discuss the main hurdles in the development of biofilm dispersal agents in order to provide a rationale for multi-targeted therapy strategies that target the complicated biofilms. Biofilm dispersal is a promising research direction to treat biofilm-associated infections in the future, and more in vivo experiments should be performed to ensure the efficacy of these therapeutic agents before being used in clinic. MDPI 2020-08-11 /pmc/articles/PMC7465149/ /pubmed/32796745 http://dx.doi.org/10.3390/microorganisms8081222 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jiang, Yu Geng, Mengxin Bai, Liping Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title | Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title_full | Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title_fullStr | Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title_full_unstemmed | Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title_short | Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles |
title_sort | targeting biofilms therapy: current research strategies and development hurdles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465149/ https://www.ncbi.nlm.nih.gov/pubmed/32796745 http://dx.doi.org/10.3390/microorganisms8081222 |
work_keys_str_mv | AT jiangyu targetingbiofilmstherapycurrentresearchstrategiesanddevelopmenthurdles AT gengmengxin targetingbiofilmstherapycurrentresearchstrategiesanddevelopmenthurdles AT bailiping targetingbiofilmstherapycurrentresearchstrategiesanddevelopmenthurdles |